BPO for rosacea? Microencapsulation technology makes it possible

Sponsored by Galderma.

Benzoyl peroxide (BPO) is a trusted compound amongst dermatologists.2,5 While its precise mechanism of action is unknown, BPO is thought to have complementary properties to effectively treat papulopustular rosacea.1,2,5 Knowing sensitive rosacea skin historically hasn’t been suitable for treatment with traditional BPO, Galderma has delivered a solution that harnesses its power through microencapsulation technology.1,3,5,6,11

The first-ever encapsulated benzoyl peroxide (E-BPO) for rosacea1,3,5,6

EPSOLAY® (benzoyl peroxide) cream, 5% is a groundbreaking topical treatment that uses microencapsulation technology to gradually release BPO for efficacious yet tolerable relief from the inflammatory lesions of rosacea.1

Unexpected tolerability

Advanced proprietary microencapsulation technology offers a unique mechanism of release by controlling the release of BPO onto the skin.1,8

  • Built-in barrier: Microencapsulation technology features a shell structure made from layers of silicon dioxide. BPO is encapsulated at the core (ie, E-BPO). When applied, the silica shells create a barrier between the skin and the active ingredient1,8
  • Controlled release: Silica encapsulation controls the BPO release rate, allowing for gradual release over time8
  • Tolerable relief: The controlled release of BPO over time allows for efficacious yet tolerable relief from the inflammatory lesions of rosacea1,8

While the precise mechanism of action of BPO in the treatment of the inflammatory lesions of rosacea is unknown, it has complementary properties that are thought to bring relief to patients. This includes potential anti-inflammatory and antimicrobial effects without the risk of antibiotic resistance.1,2

What’s more, the EPSOLAY cream vehicle contains emollients to hydrate and help improve the skin’s softness, flexibility, and smoothness; humectant to help improve skin hydration; alpha hydroxy acids to exfoliate and smooth the skin’s appearance; and no parabens.1,7-10

Visible results as early as 2 weeks

In clinical trials, many patients experienced relief as early as 2 weeks* that sustained over time with EPSOLAY cream.6,11

Study 54-02: Double-blind, randomized, vehicle-controlled safety and efficacy 12-week trial of EPSOLAY cream vs vehicle cream.1 Age: 54 | Female11

Hear from an expert and see microencapsulation technology in action

Dermatologist Dr. Hilary Baldwin discusses the state-of-the-art technology that makes EPSOLAY cream an exciting new topical proven to control the release of BPO and relieve the inflammatory lesions of rosacea.1,3,5,6

Watch the video, and learn more on the EPSOLAY cream website.

*Efficacy was evaluated in two 12-week Phase 3 pivotal trials.1,6,11

Important Safety Information

Indication: EPSOLAY® (benzoyl peroxide) Cream, 5% is indicated for the treatment of inflammatory lesions of rosacea in adults. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with EPSOLAY Cream were pain, erythema (redness), pruritus (itching) and edema (swelling), all at the application site. Warnings/Precautions: Patients using EPSOLAY Cream may experience hypersensitivity reactions, including anaphylaxis (acute allergic reaction), angioedema (rapid swelling), and urticaria (hives). If serious hypersensitivity reaction occurs, discontinue use of EPSOLAY Cream immediately and seek medical attention/initiate appropriate therapy. Skin irritation/contact dermatitis may be experienced, including erythema (redness), scaling, dryness, and stinging/burning. Irritation and contact dermatitis may occur. Use a moisturizer and discontinue EPSOLAY Cream if symptoms do not improve. Avoid application to cuts, abrasions, eczematous, or sunburned skin. EPSOLAY Cream may increase photosensitivity, sensitivity to ultraviolet light. Minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment). Use sunscreen or protective clothing when sun exposure cannot be avoided. Discontinue use of EPSOLAY Cream at the first evidence of sunburn.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088

Please see full Prescribing Information.

References: 1. EPSOLAY (benzoyl peroxide) cream, 5% [Prescribing Information]. Whippany, NJ: Sol-Gel Technologies Ltd.; April 2021. 2. Oztürkcan S, Ermertcan AT, Sahin MT, Afşar FS. Efficiency of benzoyl peroxide-erythromycin gel in comparison with metronidazole gel in the treatment of acne rosacea. J Dermatol. 2004;31:610-617. doi:10.1111/j.1346-8138.2004.tb00566.x 3. Leyden JJ. Randomized, phase 2, dose-ranging study in the treatment of rosacea with encapsulated benzoyl peroxide gel. J Drugs Dermatol. 2014;13(6):685-688. 4. Galderma Laboratories, L.P. Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®. April 25, 2022. Accessed May 11, 2022. https://www.galderma.com/us/news/sol-gel-technologies-and-galderma-announce-fda-approval-epsolay 5. Data on File. Galderma Laboratories, L.P. 6. Galderma Laboratories, L.P.; data on file. Clinical Study Report SGT-54-01; January 8, 2020. 7. Kraft JN, Lynde CW. Moisturizers: what they are and a practical approach to product selection. Skin Therapy Lett. 2005;10(5):1-12. 8. Wan DC, Wong VW, Longaker MT, Yang GP, Wei F. Moisturizing different racial skin types. J Clin Aesthet Dermatol. 2014;7(6):25-32. 9. Tang S, Yang J. Dual effects of alpha-hydroxy acids on the skin. Molecules. 2018;23(863):1-12. doi:10.3390/molecules23040863 10. Babilas P, Knie U, Abels C. Cosmetic and dermatologic use of alpha hydroxy acids. J Dtsch Dermatol Ges. 2012;10:488-491. doi:10.1111/j.1610-0387.2012.07939.x 11. Galderma Laboratories, L.P.; data on file. Clinical Study Report SGT-54-02; March 26, 2020.

For healthcare professionals only.

©2022 Galderma Laboratories, LP. All Rights Reserved.

All trademarks are the property of their respective owners.

US-EPC-2200095 May 2022